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Abstract
Background Electrical stimulation of the lower esopha-
geal sphincter (LES) improves LES pressure without
interfering with LES relaxation. The aim of this open-label
pilot trial was to evaluate the safety and efficacy of long-
term LES stimulation using a permanently implanted LES
stimulator in patients with gastroesophageal reflux disease
(GERD).
Methods GERD patients who were at least partially
responsive to proton pump inhibitors (PPI) with abnormal
esophageal pH, hiatal hernia B3 cm, and esophagitis BLA
grade C were included. Bipolar stitch electrodes were
placed in the LES and an IPG was placed in a subcutaneous
pocket. Electrical stimulation was delivered at 20 Hz, 215
ls, 3–8 mA in 30 min sessions. The number and timing of
sessions was tailored to each patient’s GERD profile.
Patients were evaluated using GERD-HRQL, daily symp-
tom and medication diaries, SF-12, esophageal pH, and
high-resolution manometry.
Results 24 patients (mean age = 53 years,
SD = 12 years; 14 men) were implanted; 23 completed
their 6-month evaluation. Median GERD-HRQL scores at
6 months was 2.0 (IQR = 0–5.5) and was significantly
better than both baseline on-PPI [9.0 (range = 6.0–10.0);
p \ 0.001] and off-PPI [23 (21–25); p \ 0.001] GERD-
HRQL. Median% 24-h esophageal pH \ 4.0 at baseline
was 10.1 and improved to 5.1 at 6 months (p \ 0.001). At
their 6-month follow-up, 91 % (21/23) of the patients were
off PPI and had significantly better median GERD-HRQL
on LES stimulation compared to their on-PPI GERD-
HRQL at baseline (9.0 vs. 2.0; p \ 0.001). There were no
unanticipated implantation- or stimulation-related adverse
events or untoward sensation due to stimulation. There
were no reports of treatment-related dysphagia, and man-
ometric swallow was also unaffected.
Conclusions Electrical stimulation of the LES is safe and
effective for treating GERD. There is a significant and
sustained improvement in GERD symptoms, esophageal
pH, and reduction in PPI usage without any side effects
with the therapy. Furthermore, the therapy can be opti-
mized to address an individual patient’s disease.
Keywords GERD  Electrical stimulation  Surgical
treatment  Refractory GERD
Gastroesophageal reflux disease (GERD) is among the
most common gastrointestinal disorders [1]. Heartburn
afflicts nearly two-thirds of US adults at some point in their
lives and accounts for 4–5 million physician office visits
every year [2]. The total annual cost of care because of
GERD in the US is estimated at $9.8 billion, $5.8 billion of
which is spent on medications [1]. From a physiological
perspective, GERD results from failure of the antireflux
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function of the lower esophageal sphincter (LES), allowing
abnormal reflux of gastric contents into the esophagus [3].
Medical therapy with acid suppression fails to address this
pathophysiology and bothersome symptoms related to
weakly acidic or nonacidic reflux or nocturnal GERD
persist in 38 % of patients [4]. Laparoscopic fundoplication
is currently the mainstay of surgical GERD therapy and is
offered primarily to those in whom medical therapy fails.
In high-volume centers, the efficacy of surgical fundopli-
cation is comparable or better than that of chronic medical
therapy [3]. However, due to concerns about long-term
failure, morbidity, and long-term side effects associated
with antireflux surgery, only a small fraction of GERD
sufferers refractory to medical therapy are referred for
surgery, leaving a significant number of these patients
without an effective therapeutic option. This unmet medi-
cal need has led to multiple attempts at development of less
invasive endoscopic and surgical devices for the treatment
of GERD.
Electrical stimulation of the LES in both acute and
chronic animal models has been shown to increase resting
LES pressure [5–7]. Short-term electrical stimulation using
temporary leads implanted in the LES in subjects with
GERD has shown similar results without interfering with
physiological LES relaxation, suggesting that this may be
an effective method of restoring the antireflux function of
diseased LES without interference with normal LES
relaxation [8, 17].
The LES Stimulation System (EndoStim BV, the Hague,
Netherlands) is an implantable electrical stimulator that
delivers long-term electrical stimulation therapy to the
LES. The objectives of this open-label human trial were to
assess the safety of chronic electrical stimulation of the
LES and to evaluate the effect of such stimulation on
GERD symptoms and medication use, esophageal acid
exposure and esophageal motor function in patients with
GERD.
Materials and methods
Study design and patient selection
This was a prospective, open-label, single-center, treat-
ment-only trial. The study was approved by the Institu-
tional Review Board of Clinica Indisa, Santiago, Chile. All
subjects signed an informed consent form. The study’s
inclusion and exclusion criteria are listed in Table 1.
LES stimulation system
The LES Stimulation System comprises three components:
a bipolar stimulation lead with two stitch electrodes, an
implantable pulse generator (IPG), and an external pro-
grammer (Fig.2a). The stimulation lead is 45 cm long and
has sterile, bipolar, stitch platinum-iridium electrodes at the
end that are implanted in the LES. The IPG is of typical
titanium case construction. The IPG contains a medical-
grade lithium battery, microelectronics, communication
coils, and an accelerometer for sensing patient posture. It is
hermetically sealed to prevent damage to the device from
biological fluids. The IPG is connected to the stimulation
Table 1 Study inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
a. 21–65 years of age a. Non-GERD esophageal motility disorders or gastroparesis
b. Heartburn, regurgitation, or both for[6 months necessitating daily
use of PPI
b. Subject has significant multisystem diseases (e.g., scleroderma,
dermatomyositis, CREST, Sjo¨gren’s, Sharp’s syndrome, etc.)
c. Baseline GERD-HRQL heartburn score of C20 off PPI with at least
10-point improvement on PPI
c. Barrett ([M2; [C1) or any dysplasia
d. American Society of Anesthesiologists (ASA) physical status
classification \II
d. Hiatus hernia [3 cm
e. Distal esophageal pH \ 4 on 24-h pH-metry off antisecretory
therapy for [5 %
e. Body mass index [35 kg/m2
f. Resting LES EEP C5 mmHg and B15 mmHg; esophageal body
contraction amplitude [30 mmHg for [70 % of swallows and
[50 % peristaltic contractions
f. Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus
(T2DM) defined as HbA1c [9.5 in the previous 6 months, or T2DM
for [10 years
g. Esophagitis B grade C (LA classification) g. Suspected or confirmed esophageal or gastric malignancy or varices
h. Signed informed consent h. Significant cardiac arrhythmia, ectopy, significant cardiovascular
disease
i. Implanted electromedical device (e.g., pacemaker)
j. Pregnancy
k. Esophageal or gastric surgery, including antireflux surgery
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leads and is permanently implanted in a subcutaneous
pocket in the left upper quadrant of the abdomen. An
external programmer, similar to other neurostimulator
programmers, allows for wireless interrogation and pro-
gramming of the IPG via laptop PC software (Fig. 2b).
LES stimulator implant procedure
The LES stimulator implant procedure is performed using
standard laparoscopic techniques. The patient is positioned
in a mild reverse Trendelenburg position. Before scrub-
bing, the skin incision for the subcutaneous pulse generator
is marked at 3–5 cm below the left costal line and parallel
to it with lateral tendency. The abdomen is prepped and
draped in the usual sterile manner. Entry to the abdominal
cavity is gained using open, Veress needle, or optics-gui-
ded access at a supraumbilical position and pneumoperi-
toneum is induced.
Four trocars are placed under direct vision as follows:
two working ports at the upper right quadrant, one in the
subxiphoid region for a liver retractor, and one on the
subcostal left anterior axillary line (preferably along the
pulse generator’s skin incision mark) for the assistant’s
instruments. One port needs to be a 10 mm port to allow
for lead introduction into the abdominal cavity, and other
ports could be 5 or 3 mm ports.
The anterior right aspect of the abdominal esophagus is
exposed using a cautery hook or a harmonic scalpel and
blunt dissection. Attention is paid to minimize thermal
damage to any nerve branches in this area. The pars flac-
cida of the hepatogastric ligament as well as the
Fig. 1 Trial Design and Follow-up. - in person visit; - phone visit
Fig. 3 LES electrode position and IPG implant location. Bipolar
stitch electrodes are placed in the abdominal esophagus inline 1 cm
apart. The lead is connected to the IPG that is implanted in the
subcutaneous pocket in the anterior abdomen
Fig. 2 a LES Stimulation System (EndoStim BV, the Netherlands)
comprises an IPG (65 mm 9 48 mm 9 12 mm, weight = 49 g) that
is implanted in the subcutaneous pocket in the anterior abdomen and
the bipolar electrodes are implanted in the LES and connected to the
IPG. b The programmer is used to wirelessly program the IPG using a
radiofrequency signal
Surg Endosc (2013) 27:1083–1092 1085
123
paraesophageal fat pad are dissected to expose a rectan-
gular longitudinal area of 3 9 1 cm. Attempts should be
made to avoid dissection of the phrenoesophageal attach-
ment and damage to the anterior vagal nerve. It is recom-
mended that any hiatal hernia present be appropriately
repaired using standard surgical techniques. If required,
dissection of both crura for transhiatal mobilization of the
distal esophagus so as to achieve 2–3 cm of tension-free
abdominal esophagus for lead implantation followed by
crural closure posteriorly with nonabsorbable sutures is
recommended.
After endoscopic exploration of the esophagus, the
Z-line is identified by transillumination. Placement of the
electrodes is performed under endoscopic visualization to
avoid perforation of the esophageal lumen.
The bifurcated bipolar lead is then completely intro-
duced into the abdominal cavity. A left caudal retraction is
applied to the gastric cardia by an assistant using an
atraumatic grasper. The guiding needle of the first elec-
trode is passed in the esophageal wall taking a 15 mm
superficial longitudinal bite at the anterior right aspect of
the esophagus above the Z-line, avoiding the anterior vagal
branch as well as arterial and venous branches of the left
gastric vessels. The electrode is placed in the muscularis
propria of the LES. The second electrode is placed in
similar fashion in an inline position and approximately
10 mm distal to the first electrode (Fig. 3).
Two titanium clips are placed on the nylon thread of
each electrode as it comes out of the esophageal muscle.
These clips serve as distal stoppers. The proximal part of
each electrode is anchored to the underlying muscle using 2
or 3/0 multifilament, nonabsorbable thread which is applied
at both sides of each silicone ‘‘butterfly.’’ Repair of any
hiatal hernia was not performed in this trial.
The abdomen is desufflated and the skin incision for the
pulse generator is made. A subcutaneous pocket is created
by blunt dissection. Pneumoperitoneum is reinduced and a
small-caliber trocar is used to puncture the fascia only,
through the skin incision, to pull the lead electrical con-
nector toward the pulse generator’s pocket. After thorough
cleaning, the connector is attached to the pulse generator
and a functionality test is performed by the technical sup-
port personnel. The pulse generator is placed into its pocket
and excess lead is simultaneously pulled into the abdomi-
nal cavity and placed along the left abdominal wall away
from the midline (Fig. 3).
The abdomen is desufflated and a final functionality test
is performed. The subcutaneous tissue is carefully sutured
above the pulse generator and the skin is sutured. The skin
trocar wounds are treated and bandaged. The patient is
discharged home after an overnight stay. It is recom-
mended that the patient wear an elastic compression ban-
dage over the pulse generator implantation site for
10–14 days in order to reduce the chances of seroma for-
mation. A check of the implant site is recommended
10–14 days after the procedure.
LES electrical stimulation is initiated 12 h after the
implant procedure. The LES Stimulation System delivers
therapy personalized to the individual patient’s needs.
Electrical stimulation is delivered using a 215-ls pulse at
20 Hz and 3–8 mA in 30 min sessions. The number and
timing of stimulation sessions were tailored to each
patient’s reflux profile which was developed using 24-h
Table 2 Baseline patient characteristics and relevant medical/GERD
history
Characteristic N Mean (SD)
Age (years) 24 52 (11.6)






Overweight (C25 and \30) 14
Obese (C30) 7
Patients using daily PPI 100 %
Duration of GERD symptoms [mean (SD)] [11 (8) years
Median (quartile) [10 (7–14) years
Duration of PPI use [mean (SD)] [5.8 (3.3) years
Median (quartile) [5.5 (3–10) years
GERD-HRQL total score On PPI Off PPI
Mean (SD) 10.4 (6.8) 23.7 (3.5)
Median (IQR) 9 (6–10) 23.5 (21–25.8)
% not satisfied 71 92
Heartburn frequency/week
Mean (SD) NC 93 % (10)
Median (IQR) 100 % (86–100)
Regurgitation frequency/week
Mean (SD) NC 67 % (38)
Median (IQR) 93 % (30–98)
Nocturnal heartburn frequency/week
Mean (SD) NC 59 % (35)
Median (IQR) 71 % (29–89)
Nocturnal regurgitation frequency/week
Mean (SD) NC 39 % (38)
Median (IQR) 31 % (0–81)
Total % time pH \ 4 [mean (SD)] 11.4 ± 5.9
Median (IQR) 10.1 (7.7–15.5)
Esophagitis (%) grade A/B/C 66.7/25.0/8.3
Hiatal hernia (%) None/\2 cm/C2 cm 87.5/4.2/8.3
SD standard deviation, IQR interquartile range, NC diary data on PPI
at baseline was not collected
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esophageal acid exposure data and patient-reported meal
and symptom times. Using the external programmer, the
stimulation parameters can be adjusted, additional sessions
can be added, or timing of existing sessions can be modi-
fied at patient follow-up to address any residual symptoms
from initially programmed therapy. The device uses an
accelerometer to detect the supine position and can deliver
additional sessions to address supine/nocturnal reflux.
The battery life of the IPG with typical use is[10 years,
after which it can be replaced using a simple outpatient
procedure under local anesthesia without the need for
repeat laparoscopy.
Conduct of the study
Patients who signed an informed consent form and met all
the inclusion and exclusion criteria underwent laparoscopic
implant of the LES stimulator as described above. The
electrical stimulation therapy was initiated on day 1 post
implantation and PPI therapy was discontinued. The fol-
low-up schedule is shown in Figure 1. Adjustments of
stimulation parameters were performed as needed based on
any residual patient symptoms reported on follow-up and
any significant acid exposure events recorded during the
24-h pH measurements.
Study objectives
The incidence of serious device- and procedure-related
adverse effects was the primary safety end point, and the
incidence of nonserious device- and procedure-related
adverse effects was the secondary safety end point.
Reduction in the patient’s heartburn symptoms (calculated
using the first 9 questions from the GERD-HRQL [health-
related quality of life] questionnaire) after 6 months on LES
electrical stimulation therapy compared with their baseline
scores was the efficacy end point. Other efficacy end points
were improvement in esophageal pH exposure, defined as
the percentage of 24-h that distal esophageal pH was\4.0 at
6 months post implant compared with baseline. Improve-
ment in esophagitis, improvement in mean and end-expi-
ratory LES pressure, improvement in daily symptom diary
results, reduction in PPI usage, and improvement in SF-12
physical and mental health scores at 6 months compared to
baseline for all variables were also considered as secondary
efficacy end points. The pH data underwent a blinded
review by an independent reviewer (MDC) blinded to the
patient and to the time data on each pH study.
Analysis
22 patients were required to have a 90 % chance of detecting,
as significant at the 5 % level, a 10-point improvement in the
GERD-HRQL score from baseline to 6 months, assuming a
standard deviation of 10 points. Allowing for an approxi-
mately 10 % patient dropout rate, a sample size of 25 patients
was chosen as the final enrollment target for the trial.
Safety evaluation was descriptive and included the
incidence, severity, and type of adverse events and clini-
cally significant changes or abnormalities in the patient’s
physical examination, vital signs, clinical tests, and EKG
results. Any reasons for discontinuation of study treatment
were reported.
The effect of electrical stimulation of the LES on patient
symptoms was measured using GERD-HRQL (on PPI and
2 weeks off PPI), symptoms and medication use reported
in a daily diary, and general quality of life measured using
SF-12 (on PPI and 2 weeks off PPI) using related-samples
Wilcoxon signed-rank test. Change in esophagitis grade,
% time distal esophageal pH was \4.0, and LES pressure
and function were assessed by comparing the results at
baseline to the 3-month follow-up. LES electrical stimu-
lation therapy (EST) was evaluated using related-samples




25 GERD patients on chronic acid-suppressive therapy
who met inclusion and exclusion criteria underwent suc-
cessful laparoscopic implantation of the LES Stimulation
System. One patient withdrew consent after 2 weeks of
therapy, despite having favorable symptom response to
therapy and without any side effects because of anxiety
related to the device and the multiple invasive tests
required by the protocol. The patient underwent an
uneventful IPG explant under local anesthesia 6 weeks
after implantation; the leads were left in situ. The
remaining 24 patients (14 men, mean age = 52 years,
SD = 11.6) were on LES EST and 23 completed their
6-month follow-up. One patient did not attend his 6-month
follow-up visit. Baseline patient and disease characteristics
are provided in Table 2.
Safety
A total of 32 adverse events were reported in 14 patients.
One adverse event was reported as ‘‘serious adverse event
not related to the device or treatment.’’ This event was an
episode of chest discomfort with mild sinus tachycardia
that was not temporally related to a session of electrical
stimulation. The patient reported similar uninvestigated
episodes in the past, prior to starting LES electrical
Surg Endosc (2013) 27:1083–1092 1087
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stimulation. The episode subsided spontaneously. The
patient was hospitalized and an emergent cardiac cathe-
terization was performed that revealed normal coronary
anatomy. Chest X-ray revealed stable lead position in the
abdominal esophagus without any evidence of migration.
The patient was diagnosed with esophageal spasm, treated
medically with antispasmodics, and has not had a recur-
rence of this symptom despite continued electrical stimu-
lation therapy. The remaining 31 adverse events were not
serious. Five events in four patients were reported as pos-
sibly or definitely device-related (three implant site pain,
one localized infection, one dyspepsia) and seven events in
six patients were reported as laparoscopic implant proce-
dure-related (three implant site pain, three postoperative
nausea, one localized infection). None of the patients
complained of gastrointestinal side effects of bloating,
inability to belch, or new dysphagia associated with LES
EST throughout their 6-month follow-up.
Patients GERD symptoms as measured by GERD-
HRQL and daily symptom diaries
Patients GERD symptoms improved soon after initiating
the electrical stimulation and continued to improve over the
first 2–3 months with optimization of EST to an individual
patient’s needs. Patients reported better symptom control
at 3 and 6 months compared to baseline on and off PPI.
GERD-HRQL composite and individual question scores at
6 months were statistically significantly better than on- and
off-PPI scores at baseline (Table 3; Fig. 4). At baseline,
92 % of the subjects reported that they were ‘‘unsatisfied’’
with their condition off PPI and 71 % on PPI compared to
4 % were ‘‘unsatisfied’’ at their 6-month evaluation on LES
EST. The patients’ satisfaction with their condition at
6 months was statistically significantly better than both on-
PPI (p \ 0.001) and off-PPI (p \ 0.001) baseline
satisfaction.
21 patients were available for pairwise analysis of
symptoms of heartburn and regurgitation evaluated using
the 14-day symptom diary. The diary data on daily patient
Fig. 4 Significant improvement in median (IQR) GERD-HRQL
composite score at months 3 and 6 compared to baseline on-PPI
and off-PPI median GERD-HRQL composite scores. There was small
but statistically nonsignificant improvement from month 3 to 6
Table 3 Baseline and post-LES electrical stimulation therapy results
Baseline Month 6 p value
GERD-HRQL
On PPI (n = 22) [median (IQR)] 9.0 (6–10) 2.0 (0–4.0) \0.001
Off PPI (n = 24) 23.5 (21–25.75) \0.001
SF-12 Mental Health [median (IQR)]
On PPI (n = 22) 45.0 (41.5–55.0) 53.0 (48.0–62.0) 0.03
Off PPI (n = 24) 49.0 (35.5–54.8) 0.006
SF-12 Physical Health [median (IQR)]
On PPI (n = 22) 47.0 (41.8–52.8) 54.0 (44.0–55.8) 0.11
Off PPI (n = 24) 45.5 (39.8–48.0) 0.005
% 24-h esophageal pH \ 4.0 [median (IQR)] 10.1 (7.7–15.5) 5.1 (2.8–8.4) \0.001
% 24-h esophageal pH \ 4.0 upright 10.4 (8.0–15.2) 3.2 (2.5–7.4) \0.001
% 24-h esophageal pH \ 4.0 supine 6.0 (1.8–15.5) 5.7 (0.9–9.9) 0.38
DeMeester score 36.7 (29.4–61.4) 24.5 (13.4–37.9) 0.002
% patients reporting heartburn affecting sleepa
On PPI 70.8 4.3 0.001
Off PPI 95.8 \0.001
% patients reporting dysphagia/odynophagiaa
On PPI 37.5/25 4.3/0 0.02/0.13
Off PPI 66.7/83.3 \0.001/\0.001
Trial design was an in-person visit (phone visit)
a Bothersome symptoms with GERD-HRQL scores C2 on individual question
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symptoms of heartburn and regurgitation is provided in
Fig. 6. There was statistically significant improvement in
frequency and severity of symptoms of both heartburn and
regurgitation over time with LES stimulation therapy. At
baseline all patients were on antisecretory medications
(proton pump inhibitors) for their GERD. At the evaluation
after 6 months on LES stimulation therapy, 21 patients
were able to completely stop PPI use, whereas 2 patients
reported intermittent use of antisecretory medications in
the 14 diary days prior to their 6-month follow-up visit.
One patient each reported using PPI [ 50 % and B50 % of
the diary days.
Esophageal pH and high-resolution manometry
23 patients underwent esophageal pH testing at baseline
and at 12 and 24 weeks after implant. One patient did not
tolerate the tube pH testing at the 12-week follow-up,
removed the pH tube a few hours after insertion, and
refused repeat testing at both 12 and 24 weeks. Blinded pH
analysis revealed that median percent time of pH \ 4 in
24-h improved from 10.1 % at baseline to 6.6 % at
3 months to 5.1 % at 6-months (p \ 0.01). Detailed blin-
ded pH data at baseline and at 6 months are provided in
Table 3 and Fig. 5.
High-resolution manometry showed no effect of LES
electrical stimulation on esophageal body function and on
LES residual pressure. Baseline median LES end expira-
tory pressure (EEP) was 10.3 mmHg compared to the
3-month value of 15.7 mmHg (p = 0.001). Patients’
baseline median LES mean pressure (MP) was
17.8 mmHg, and at the 3-month evaluation on LES stim-
ulation therapy it was 22.6 mmHg (p = 0.002).
General quality of life as measured by SF-12
There was a significant improvement in the patients’ gen-
eral quality-of-life score as measured by SF-12 after
6 months on LES EST compared to their baseline scores
(Table 3).
Healing of erosive esophagitis
At baseline endoscopy, 67, 25, and 8 % of patients had LA
grade A, B, and C esophagitis, respectively. At their
3-month evaluation endoscopy, 44 % of patients had no
esophagitis while 35, 17, and 4 % of patients had LA grade
A, B, and C esophagitis, respectively (p \ 0.01; related
sample Wilcoxon signed-rank test). Improvement in
esophagitis by at least 1 grade was reported in 56 % of
patients at their 3-month endoscopy.
Discussion
This is the first human trial of long-term electrical stimu-
lation as a treatment for GERD. The results show that
electrical stimulation of the LES can safely improve
symptoms of GERD as measured by GERD-HRQL and the
patient symptoms diary, reduce esophageal acid exposure
by augmenting esophageal sphincter pressures, and elimi-
nate the need for PPI medications without the GI side
effects typically seen with other antireflux procedures that
involve mechanical alteration of the gastroesophageal
junction. LES EST was not associated with any adverse
effects or sensation and specifically did not interfere with
physiological LES relaxation and hence there was no
dysphagia.
GERD is ‘‘a condition which develops when the reflux
of stomach contents causes troublesome symptoms and/or
complications’’ [9]. Society of American gastrointestinal
endoscopic surgeons guidelines for surgical treatment of
GERD recommend surgery for individuals who have failed
medical management (inadequate symptom control, severe
regurgitation not controlled with acid suppression, or
medication side effects) or opt for surgery despite suc-
cessful medical management (due to quality-of-life con-
siderations, lifelong need for medication intake, expense of
medications) [3]. On the other hand, the AGA position
statement on management of GERD recommends antire-
flux surgery for GERD patients who are responsive to but
intolerant of acid suppressive therapy or for patients with
persistent and troublesome GERD symptoms despite
medical therapy. The AGA statement warns of deleterious
GI side effects from an antireflux procedure [10].
Limitations and concerns with current medical and
surgical treatments leave a significant GERD patient pop-
ulation whose symptoms are not adequately controlled with
medical management and seek a valid therapeutic option as
an alternative to surgical fundoplication [11–13]. This has
led to a search for an alternative, less invasive treatment for
Fig. 5 Change in median IQR distal esophageal pH on LES electrical
stimulation from baseline to 3 months (n = 24) and 6 months
(n = 23). Related sample Wilcoxon signed-rank test was used to
compare the pH at various time points
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GERD that would address all the symptoms of GERD
without deleterious side effects. Various endoscopic
methods have been developed and approved but only a few
are currently available for clinical use [14]. Most of these
therapies were removed from the market due to lack of
efficacy or serious adverse events. Currently approved as
an alternative therapy for GERD is EsophyX TIF
(transoral incisionless fundoplication) (EndoGastric Solu-
tions, Redmond City, CA), which uses T-tags in an attempt
to create an endoscopic fundoplication, and the LINX
reflux management system (Torax Medical, Inc., Shore-
view, MN), which uses a bracelet of magnets encased in
titanium placed around the LES to create a ‘‘magnetic
sphincter’’ [15, 16].
Treatment goals established by the SAGES for an anti-
reflux device include elimination of symptoms, healing of
esophagitis, prevention of complications, and maintenance
of remission [3]. Our results suggest that application of
long-term electrical stimulation to the LES using the per-
manently implanted LES Stimulation System may fulfill all
these goals. LES stimulation resulted in significant
enhancement of LES pressure and significant reduction in
distal esophageal acid exposure, which in turn resulted in a
significant improvement in GERD symptoms and patient
quality of life. The improvement in symptoms was sus-
tained over the 6-month follow-up period and continued to
improve over time due to optimization of therapy to
address each patient’s symptoms without any signs of
adaptation and/or muscle fatigue. Our patients reported
better GERD-HRQL scores and better satisfaction with
LES EST than baseline on-PPI scores as LES electrical
stimulation addressed global GERD symptoms, including
regurgitation. Regurgitation is a symptom usually not
responsive to medical therapy and has been cited as an
appropriate indication for an antireflux procedure. There
was a complete elimination of the symptom of regurgita-
tion at the 6-month evaluation on LES stimulation as
reported in the daily diaries. There was significant healing
of erosive esophagitis at the 3-month endoscopy.
Most importantly, electrical stimulation of the LES had
no effect on LES residual pressure, and none of the patients
in this trial reported dysphagia or any other GI symptoms
on LES stimulation therapy. GI side effects such as dys-
phagia, gas bloat, flatulence, and diarrhea have been the
Achilles heel of all antireflux procedures. Significant
postoperative rates of dysphagia with antireflux surgery,
Fig. 6 Median % daily diary days with symptoms of nocturnal and daytime regurgitation (A) and heartburn (B), and % of the diary days with
various severity levels of regurgitation (C) and heartburn (D) at 1, 3, and 6 months compared to the baseline
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requiring endoscopic dilation, ranging from 0 to 25 % and
a reoperation rate ranging from 1.8 to 10.8 % have been
reported [3]. Significantly higher levels of bloating and
flatulence are also reported with antireflux surgery com-
pared to antisecretory therapy over long-term (5-year)
follow-up [18]. Of particular importance is the excellent
safety profile of LES electrical stimulation therapy. There
have been no device- or procedure-related serious adverse
effects during implantation or during the 6-month study.
There were a few minor anticipated adverse effects
reported with the surgical implant procedure, which is
expected. Previous experience with electrical stimulation
of the stomach, using comparable electrodes and devices
for the purpose of treating gastroparesis, diabetes, and
obesity, has also shown an excellent safety and side-effect
profile [19]. This improved safety profile of LES electrical
stimulation may result in better patient acceptance of EST
as an antireflux procedure and expand this option to a
larger group of patients suffering from refractory GERD.
Another issue with antireflux surgery is the learning
curve. Antireflux surgery performed by less experienced
individuals can result in suboptimal failure rates, compli-
cations, reoperations, operative time, hospital days, and
conversion to open surgery [20, 21]. Reports suggest that
outcomes of high-volume referral centers are significantly
better than those seen in low-volume centers [13, 18]. The
LES stimulation implant procedure is quiet simple and can
easily be standardized for uniform performance by general
laparoscopic surgeons. The ability to optimize the therapy
noninvasively over time allows for fine-tuning of GERD
therapy at patient follow-up to continually improve GERD
outcomes, an option not available with current endoscopic
or laparoscopic antireflux procedures.
There are limitations to this study. We enrolled patients
who were at least partial responders to PPIs and our results
may not apply to patients who are complete nonresponders
to PPI therapy. However, symptoms of nonresponders to
PPI maybe caused by nonreflux conditions such as visceral
hypersensitivity or an esophageal motility disorder and
they may not respond to antireflux therapy. Because of
these reasons, response to medical therapy has been com-
monly used to select patients for both endoscopic and
surgical antireflux procedures. Also, this was an open-label
study and hence the placebo effect may have contributed to
improvement in symptoms and a ‘‘regression to mean’’
effect could have contributed to improvement in physio-
logical variables such as esophageal pH.
In addition, patients with severe LES dysfunction (LES
end-expiratory pressure \5 mmHg), significant hiatal her-
nia of [3 cm, and grade D esophagitis were not evaluated
in this trial. These patients usually have severe LES dys-
function or a significant alteration in their gastroesophageal
anatomy that may not be amenable to correction with
electrical stimulation of the LES. Patients who have
moderate anatomical disruption of the GEJ anatomy, i.e.,
hiatal hernia of 3–5 cm, could be addressed with a com-
bination of restoration of abdominal esophagus, repair of
the diaphragmatic hiatus, and implant of the LES stimu-
lator, thus avoiding fundoplication and reducing long-term
side effects associated with the fundoplication. However,
this technique needs to be evaluated in a prospective
clinical trial.
Future improvements to the surgical implant procedure,
including options for single-port, periumbilical single-site
access and use of mainly 3-mm trocars and instruments,
may further improve patient acceptability of the surgical
procedure. In leaner patients with a normal, nonfatty liver,
the liver retractor can be replaced with a V-shaped extra-
corporeal knotted thread. Moreover, by using a longer lead
body, the skin incision for the subcutaneous stimulator
could be made below the ‘‘bikini line’’ for better cosmetic
outcome.
In conclusion, our long-term results show that electrical
stimulation of the LES using the laparoscopically implan-
ted LES Stimulation System is safe and effective in the
treatment of GERD. LES EST results in significant
improvement in patient GERD symptoms of heartburn and
regurgitation, reduction in GERD medication use, reduc-
tion in esophageal acid exposure, and improvement in LES
pressures without causing adverse sensation or symptoms.
The improvement in patient outcome is sustained over
time. Furthermore, LES EST can be optimized noninva-
sively to an individual patient’s disease profile and
changing needs over time to achieve sustained improve-
ment in patient outcomes.
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